Next Article in Journal
Emotional Regulation Self-Efficacy Influences Moral Decision Making: A Non-Cooperative Game Study of the New Generation of Employees
Previous Article in Journal
Runoff Estimation of Jiulong River Based on Acoustic Doppler Current Profiler Online Monitoring Data and Its Implication for Pollutant Flux Estimation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 19
Issue 23
10.3390/ijerph192316365
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile

by
Sara Boccalini
1,*,
Benedetta Bonito
1,
Beatrice Zanella
1,
Davide Liedl
2,
Paolo Bonanni
1 and
Angela Bechini
1
1
Department of Health Sciences, University of Florence, 50134 Florence, Italy
2
Medical Specialization School of Hygiene and Preventive Medicine, University of Florence, 50134 Florence, Italy
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2022, 19(23), 16365; https://doi.org/10.3390/ijerph192316365
Submission received: 26 October 2022 / Revised: 24 November 2022 / Accepted: 1 December 2022 / Published: 6 December 2022
(This article belongs to the Special Issue The Impacts of Health Intervention on Cancer Epidemiology)
Browse Figures
Versions Notes

Abstract

:
In 1991, Italy was one of the first countries worldwide to introduce a universal hepatitis-B vaccination for children. Since then, epidemiological data have clearly demonstrated the huge clinical benefits of the vaccination. The aim of this study was to update the favorable economic impact of the hepatitis B virus (HBV) vaccination, 30 years after its implementation. A mathematical model was developed to simulate the clinical/economic impact of the universal HBV-vaccination program versus a hypothetical no-vaccination scenario as a posteriori analysis. We assessed the vaccination benefits over a 30-year-immunization-period (1991–2020), and the following period, 2021–2070. Our data showed a big drop in HBV-related diseases (−82% in infections, chronic disease, and hepatocellular-carcinoma cases), and related costs (−67% in the immunization period and −85% in 2021–2070), attributable to vaccination. The return on investment (ROI) and the benefit-to-cost (BCR) ratios are >1 for the first thirty-year-immunization-period, and are predicted to almost triplicate the economic savings in the period 2021–2070, both for the National Health Service (NHS) and from societal perspectives. Our model confirmed that the implementation of universal HBV-vaccination in Italy during the first 30 years continues to be a cost-saving strategy, and more advantageous effects will be further achieved in the future. The HBV-vaccination strategy greatly expresses a huge impact in both the short- and long-term, and from the clinical and economic point-of-views.

1. Introduction

Hepatitis B is a liver inflammation caused by the hepatitis B virus (HBV). HBV is a small, enveloped, double-stranded DNA virus (3200 base pair) of the Hepadnaviridae family. When the infection occurs, the virus replicates in the liver cells, producing an excess of the viral-envelope protein (Hepatitis B surface antigen, HBsAg) that circulates in the blood of the host. The HBV transmission-route is both horizontal and vertical. The first occurs by exposure of contaminated blood or body fluids (such as saliva, semen, and vaginal fluids) through the percutaneous and permucosal way. Moreover, transmission may happen in the case of needlestick injury, tattooing or piercing, and the reuse of contaminated needles/syringes or sharp objects in health-care settings, in the community and household contacts, or among drug users. HBV can also spread from mother to child through perinatal transmission [1,2]. In infants and young children, the infection is generally asymptomatic, while approximately 50% of adults develop symptoms [2]. Nevertheless, in a few cases hepatitis B can be fulminant (<1%) [3]. The first-infection age affects the development of the disease: in adults, acute infection is generally self-limited, and less than 5% of cases become chronically infected. Meanwhile, acquiring the infection in the first years of life leads to chronic hepatitis (CHB) in approximately 95% of cases. The main sequelae related to chronic infection are cirrhosis and hepatocellular carcinoma (HCC) [1,2,3].
Different serological markers can describe the development of the acute and the chronic HBV infection: the hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg), hepatitis B envelope antigen (HBeAg) and their respective antibodies (anti-HBs, anti-HBc and anti-HBe). When the hepatitis B surface antigen persists in serum for more than six months after the infection, the subject is considered chronically infected [4,5]. Moreover, HBeAg can be detected in subjects with acute or chronic HBV infection, and its presence indicates viral replication and thus high viral-levels of HBV DNA and high infectivity. On the other hand, the presence of anti-HBe is generally associated with a decrease of replication activity, although a reversion to HBeAg positivity can occur. Lastly, anti-HBs is considered a marker of protection. These antibodies may be non-detectable in the serum of a chronically infected person [2].
Hepatitis B still remains a global public-health concern. The World Health Organization (WHO) estimates that in 2019, 296 million people were living with chronic HBV infection, with 1.5 million of new infections each year, and that approximately 820,000 deaths occurred due to hepatitis B sequelae, mostly cirrhosis and hepatocellular carcinoma [1]. The distribution of the HBV infection is not homogeneous around the world: in particular, Western Pacific and African regions have the highest prevalence (6.2% and 6.1%, respectively) [6]. In 2019, 30 European Union/European Economic Area (EU/EEA) member states reported 29,996 cases of HBV infection: 6% of them were reported as acute, 48% as chronic, 38% as ‘unknown’, and 7% could not be classified, due to the incompatible data-format provided. The overall rate of acute hepatitis incidence was 0.4 per 100,000 inhabitants. Moreover, the overall notification-rate on chronic-hepatitis-B infections was 4.8 cases per 100,000. The highest rate of acute infections was observed among 35–44-year-olds, and the highest rate of chronic infections among 25–34-year-olds. The overall male-to-female ratio was 1.5:1 [7].
In Italy, according to the latest SEIEVA (Sistema epidemiologico integrato epatiti virali acute—Acute Viral Hepatis Integrated Epidemiological System) bulletin, 89 acute-hepatitis-B new cases have been reported in 2021 (0.18 per 100,000 vs. 0.21 per 100,000 in 2020). The most affected age group was the 35–54 year-olds, and males were mostly represented (77.5%). Most of the reported cases occurred in non-vaccinated subjects [8]. The hepatitis B incidence has shown a relevant declining trend from five cases per 100,000 in 1991 to the current level of incidence, following the implementation of universal vaccination for the younger people affected in Italy [9].
As a matter of fact, in 1991 Italy was one of the first countries to introduce the universal anti-hepatitis B vaccination in a double-cohort strategy, for newborns and 12-year-old subjects. Since 2003, anti-hepatitis B vaccination has been kept mandatory just for newborns, in a three-dose schedule (at 3, 5, and 11 months of age) [10].
After the first six years of implementation (1991–1997), a cost-effectiveness evaluation of the Italian HBV-vaccination program was reported by Da Villa et al. This study highlighted for the first time the averted costs following the acute-hepatitis-B case drop, amounting to 2/3 of the expenses for immunization. In particular, the authors specified that the main economic goal would have been reached after 15 years of vaccination (2006), when the National Health Service (NHS) would begin to save money, thanks to the averted treatment of cirrhosis and HCC cases [11]. To confirm this last assumption, more recently, Boccalini et al. performed a new cost-effectiveness study, and remarked on the great economic impact of the universal HBV vaccination 20 years after its introduction in 1991. The results of this economic evaluation showed that the break-even points were just achieved, from both the NHS and societal perspectives. More money-saving should gradually occur from then on [12]. The aim of this study was to update the clinical and economic assessment of the HBV vaccination program in Italy, 30 years after the introduction of the immunization offer, to estimate the savings we obtain with this preventive intervention and the value of the immunization program in the future.

2. Materials and Methods

The mathematical model developed in the previous economic analysis by Boccalini et al. [12] was reviewed and updated, for the current aim. This mathematical model simulates the clinical and economic impact since the HBV vaccination strategy started in Italy in 1991, (Microsoft Excel 2010 software—Microsoft Corporation, Redmond, Washington, DC, USA).
We developed a model estimating hepatitis B disease cases and related costs, in a dual vaccination/no vaccination scenario; meanwhile, we calculated the number of hepatitis B vaccine-doses administered to infants and teenagers during 1991–2020, and the total vaccination costs. This study analyzes the burden of the hepatitis B vaccination-program during the past 30-year immunization period (1991–2020) and the following period 2021–2070, considering the latter as a time in which the acute infection acquired in the first 30 years would evolve into more severe outcomes (i.e., chronic hepatitis B, cirrhosis and hepatocellular carcinoma), and thus would need to be treated. We compared the real clinical and economic data to a hypothetical no-vaccination scenario. To do so, we assumed that acute-hepatitis-B incidence in Italy would gradually decrease, thanks to the use of general preventive measures [12]. Specifically, the impact of the vaccination program was performed both from the NHS and the societal perspectives.
The outcomes of the model were estimated considering the different health stages of the HBV disease: symptomatic acute HBV infection (AHB), chronic hepatitis B (CHB), compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and the cases of liver transplantation (LT), required in cases of DC and HCC. Our model shows what would be the number of clinical cases with and without the adoption of the vaccination program, (thus, how many cases would be avoided), and also the incidence-reduction rates. Moreover, our model calculates the annual clinical costs (direct and indirect) in a vaccination/no vaccination scenario.
Figure 1 shows the natural history of hepatitis B and the transition rates among the different health stages used in the mathematical model, according to the literature research performed in the previous study [12].
Epidemiological and economic data included in the model have been obtained or updated from the previous study led by Boccalini et al. [12]. In particular, data related to population by age group [13], life expectation [14], acute-hepatitis-B incidence rates [9], the prevalence of HBsAg-positive mothers [15,16,17] anti-HBV vaccine coverage (VC) values [18] and inflation rates [19], were updated.
To calculate the costs associated with the treatment of the diseases, we assumed that cases of AHB were treated only during the first year of diagnosis; on the other hand, costs associated with CHB were applied to all cases, considering the life-long treatment for this disease stage. According to the 5-year survival rate, CC cases were treated as CHB cases for the first 15 years, and then as cirrhosis-affected patients. Similarly, DC patients were treated as CHB for the first 15 years, then as CC for the following 3 years and finally as DC patients. HCC patients were treated as CHB for 20 years (or for 15 years, and then as CC for the following 5 years). They were then treated as HCC patients for 1 year, and subsequently for 4 years as CHB/CC (according to the survival rate), and finally as CHB/CC for 1 year (in line with life expectancy). Patients who require LT are treated simultaneously, both for the transplantation itself and for HCC/DC for 1 year. Subsequently, these patients encounter a post-transplantation follow-up period, calculated as post-transplantation survival rate and life expectancy.
Table 1 reports the time interval between hepatitis B disease stages, the median age of the patients at the time of diagnosis, and the survival rate used in the mathematical model.
Table 2 shows the annual costs of HBV diseases (referring to 1990) and the anti-hepatitis-B vaccination costs (in 1991), reported firstly by Da Villa et al. [11] and updated in line with the annual inflation-rate (provided by the Italian National Institute of Statistical—ISTAT) [19].
Importantly, the major results of the model are expressed as benefit-to-cost ratio (BCR) for the societal perspective, and return-on-investment (ROI) values for the NHS perspective. The BCR or ROI indicates the relationship between the relative costs and benefits; a value of BCR or ROI ≥ 1 represents a favorable outcome, meaning that for each euro invested in the vaccination program the same amount or more would be saved through costs avoided, thanks to the vaccination program.

3. Results

3.1. Clinical Cases Related to HBV and Related Costs, with and without the Universal HBV Vaccination-Program Implementation

The results of the mathematical model are shown in Table 3. The first thirty years of the HBV vaccination program in Italy (1991–2020) reported a marked reduction rate in the different clinical stages of the disease, compared to a hypothetical no-vaccination scenario. In particular, HBV infections and CHB cases showed a reduction rate of 82%, preventing 193,373 and 6256 cases, respectively. The reduction of the health consequences of CHB was also particularly relevant (−81% for HCC, −79% for LT, −57% for CC and DC). Moreover, the number of AHB cases was halved.
Table 4 shows the direct, indirect, and total clinical costs during two periods, 1991–2020 and 2021–2070, and, lastly, the whole period 1991–2070 in the vaccination and no-vaccination scenario. During 2021–2070, only the costs related to the later stages of the HBV infection (CHB, CC, DC, HCC, LT) occurring in the first 1991–2020-period were evaluated. The reduction rate of the direct and indirect costs was comparable in the analyzed periods. Overall, the implementation of the HBV vaccination compared with a no-vaccination scenario resulted in a reduction in clinical costs of 67% up to 2020, 85% during the 2021–2070 period, and 75% in the overall considered-period (1991–2070). Moreover, comparing the reduction rate of clinical costs in the past and in the following period, the highest savings were due to avoided CHB treatment, corresponding to a 75% reduction in 1991–2020, while in the period 2021–2070, costs due to CHB continued to decrease more consistently (−86%). However, it should be noted that the reduction of the clinical costs should be higher for all the sequela of the HBV disease compared to the previous period, especially for liver transplantation (−89%) (Figure 2).

3.2. Economic Impact of the Immunization Program

According to our mathematical model, the HBV vaccination of thirty newborn cohorts and twelve 12-year-old cohorts during the first 30 years of implementation (1991–2020) cost EUR 1,263,247,830 from the NHS perspective and EUR 1,484,792,906 from the societal perspective, resulting in net savings of EUR 396,494,926 and EUR 482,577,670 respectively (Table 5). These first thirty years of the HBV immunization-program resulted in an ROI of 1.31 and in a BCR of 1.33, leading to a relevant cost-saving profile both for the NHS and from societal perspectives. ROI and BCR rates are predicted to be higher in the whole period 1991–2070 (2.74 and 2.75, respectively), implying net savings of EUR 2,199,262,351 from the NHS perspective and EUR 2,603,584,165 from the societal perspective.

4. Discussion

The aim of this study was to confirm the favorable clinical and economic impact of an extensive universal HBV program in Italy 30 years after its introduction, as reported in the first evaluations [11,12]. As a matter of fact, more than 20 years ago, Da Villa et al. estimated a progressive increase in savings and the achievement of the main economic goal of vaccination starting from 2006, after 15 years of immunization, when money began to be saved in the treatment of cirrhosis and HCC, too [11]. This favorable assumption was confirmed after 20 years of vaccination [12]. The current study demonstrates that 30 years of mandatory anti-hepatitis B vaccination among children in Italy shows a continuous relevant clinical-impact and a cost-saving profile.
Our results related to the relevant clinical impact of immunization on the reduction of HBV disease are in line with the mathematical model developed by Goldstein et al.: the routine pediatric hepatitis-B-vaccination, with 90% of vaccination coverage and the first dose administered at birth, would prevent 84% of global HBV-related deaths [28]. Moreover, with 100% of vaccination coverage and 100% of newborns receiving a birth dose of vaccine, it would be theoretically possible to prevent 95% of all HBV-related deaths [28].
As a matter of fact, in Italy, the hepatitis B epidemiology has considerably changed, with a relevant reduction of incidence rates in these first thirty years of the universal immunization-program, as confirmed by data collected by SEIEVA [9] and many sero-epidemiological studies [29,30]. Moreover, a recent serosurvey highlighted an additional increasing trend of immunity levels acquired by the vaccination in the pediatric and adolescent population [31].
From an economic point of view, our model estimated ROI and BCR values as >1 for the first thirty-year immunization period (1991–2020), which are predicted to almost triplicate the economic savings in the period 1991–2070. This is true both for the NHS and from the societal perspectives. Moreover, the major clinical-costs are now associated with the late stages of the HBV disease, whereas during 1991–2020 they were more related to CHB. This underlines how the extensive vaccination-program has drastically reduced the number of AHB cases, and thus, the number of CHB, CC, DC, HCC and LT cases are now those which are critical to treat. The favorable impact of the anti-hepatitis B vaccination in Italy has also been confirmed by Mele et al. [32], not only for children, but also for certain risk groups, for whom it is recommended.
Our results demonstrated and confirmed how the implementation of the universal hepatitis B vaccination in Italy, which was seen as apparently expensive because of the purchase of many doses of vaccines, instead has produced consistent savings from the NHS and societal point of view in these first 30 years. Moreover, the model predicted that the hepatitis B vaccination will continue to generate savings in the following years, up to 2070. Therefore, the Italian immunization strategy results in value for health, and the current economic benefits could be addressed toward other health priorities, such as prevention activities towards vaccine-preventable diseases and other infectious or chronic diseases, in order to achieve a complete physical, mental and social state of wellbeing.
Savings generated by universal HBV vaccination could be reinvested also, in health promotion and preventive activities related to hepatitis B. For example, greater attention could be paid to protect the high-risk groups. Indeed, some hepatitis B cases occurred in subjects with a higher risk of infection, such as healthcare workers, household contacts of chronic-hepatitis-B carriers, drug users, hemodialysis subjects. and men who have sex with men [32], for whom the HBV vaccination is strongly recommended and free of charge [8,33,34,35]. Moreover, Pinon et al. found a not-always-appropriate surveillance of HBsAg-positive women during pregnancy [36]. Despite Italy providing HBV screening to pregnant women, along with timely immune-prophylaxis and hepatitis-B vaccination at birth to newborns of seropositive women [37], health authorities should consider the possibility of investing more resources also in the screening of pregnant women, in order to prevent HBV vertical-transmission. In addition, in Italy, 21.8% of children are born to at least one parent of foreign nationality [38]. Therefore, the screening of the migrant population would be a good practice to be implemented, especially for people from high-HBV endemic areas [39].
To date, the Italian population aged up to 40 years old has benefited from the universal hepatitis B vaccination, while older age groups of the general population may still be at risk of acquiring the HBV infection, particularly through indirect parenteral-transmission and sexual contact [40]. The latest Italian data highlighted beauty treatments (such as manicures, piercings, or tattoos) as the most frequently reported risk-factors for virus exposure [8,33,34,35,41]. Specific actions should be adopted to reduce hepatitis B cases caused by this way of transmission.
Lastly, it should be taken into account that approximately 5% of fully immunized subjects are non-responders. From a public-health point of view, it could be useful to assess more accurately the impact of screening programs on high-risk groups, such as workers and students in healthcare settings or subjects under chronic disease [42].
Nevertheless, independently by the shown favorable profile, it is crucial to maintain high vaccination-coverage rates in the target immunization-groups in future years, to guarantee the achievement of the hepatitis-B-elimination goal, as desired by the WHO since 2010 [43,44]. In 2016, the WHO released the first global health-sector strategy to end viral hepatitis, which adopted the call for specific actions in the fight against viral hepatitis included in Target n. 3 of the 2030 Agenda for Sustainable Development [45]. Therefore, a broad range of countries have implemented national hepatitis-elimination plans, including Italy [46]. In 2021, the WHO published interim guidance for country validation of viral-hepatitis elimination, focused mainly on hepatitis B and hepatitis C [47]. However, in Italy, after the implementation of the immunization program, HBV-vaccination coverage at 24 months reached a high level (approximately 95%). The HBV vaccination coverage dropped in the period 2014–2016 (reaching 92.9% in 2016) [18,48], and the hepatitis B vaccination was made mandatory to all 0–16-year-olds to attend school [49], in order to increase vaccination coverage. Therefore, the current benefits of the vaccination program could be targeted at maintaining vaccination coverage at high levels, to promote immunization in hesitant subjects, and to contrast vaccination hesitancy.
This study has some limitations. Firstly, as with all pharmacoeconomic analyses, it is based on a mathematical model strongly dependent on the input data used. Therefore, the robustness of our results is related to assumptions. In particular, we used the same data used by the Technical-Scientific and Health Planning Committee of the Ministry of Health. In 1991, this board originally advised and supported the decision to start universal vaccination against HBV infection for all newborns and teenagers in Italy. In order to confirm the first data reported by Da Villa et al. [11], we used the described mathematical-model, although the shift from the monovalent hepatitis-B-vaccine to combined vaccines was not considered. This shift may have reduced the cost of the hepatitis B component. In addition, the effects of co-infections with other viruses, (i.e., HCV, HDV, HIV), or from alcohol and illegal-drug consumption were not included in the analysis. We could not calculate the indirect costs of liver transplantation because of data unavailability; however, we included the medical-assistance costs but not the antiviral-drug-therapy ones (as they are particularly expensive). Therefore, our analysis represents an underestimation of the real costs for chronic-hepatitis management, which are indeed particularly remarkable for the impact of the HBV vaccination. Thus, the real beneficial effects of vaccination could be greater than our estimation. Lastly, this model could be also used to assess the clinical and economic impact of immunization strategies in other settings, (i.e., occupational exposures, hepatitis C infection and treatment, risk groups, etc.).
On the other hand, the main strength of our study is the demonstration of how the universal hepatitis-B-vaccination-program implemented in Italy has generated savings in the short- and long-term which can be reinvested in other public-health activities. In addition, it should be emphasized that this universal preventive-program continued to be favorable in Italy, where the current incidence of HBV was very low, and the specific impact of vaccination is therefore paradoxically reduced by the immunization program itself.

5. Conclusions

Despite the availability of a safe and effective vaccine, hepatitis B still represents a major public-health concern worldwide. Nevertheless, countries which implemented a strong immunization program managed to control this infectious disease. Italy was one of the first countries worldwide to introduce a universal HBV-vaccination strategy in 1991, leading to remarkable changes in the hepatitis B epidemiology. Our study confirms that the Italian hepatitis-B immunization-program, in addition to the wide reduction of HBV infections and chronic cases, cut direct and indirect costs in the short- and long-term, and is an effective investment in health value.

Author Contributions

Conceptualization, S.B. and A.B.; Methodology, S.B. and A.B.; Validation, S.B.; Formal analysis, S.B. and A.B.; Investigation, D.L.; Data curation, S.B., B.B., B.Z. and A.B.; Writing—original draft, S.B., B.B., B.Z. and A.B.; Writing—review & editing, S.B., B.B., B.Z. and A.B.; Visualization, S.B., B.B., B.Z., D.L. and A.B.; Supervision, S.B., P.B. and A.B.; Project administration, S.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study did not require ethical approval.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization (WHO). Hepatitis B. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed on 7 December 2021).
  2. Haber, P.; Schillie, S.; Hepatitis, B. Chapter 10—Epidemiology and Prevention of Vaccine-Preventable Diseases. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (accessed on 7 December 2021).
  3. Trépo, C.; Chan, H.L.; Lok, A. Hepatitis B virus infection. Lancet 2014, 384, 2053–2063. [Google Scholar] [CrossRef] [PubMed]
  4. Hoofnagle, J.H. Chronic hepatitis B. N. Engl. J. Med. 1990, 323, 337–339. [Google Scholar] [CrossRef] [PubMed]
  5. World Health Organization (WHO). The Immunological Basis for Immunization Series: Module 22: Hepatitis B. Available online: https://www.who.int/publications/i/item/who-immunological-basis-for-immunization-series-module-22-hepatitis-b (accessed on 23 November 2022).
  6. World Health Organization (WHO). Global Hepatitis Report. 2017. Available online: https://www.who.int/publications/i/item/9789241565455 (accessed on 23 November 2022).
  7. European Centre for Disease Prevention and Control (ECDC). Hepatitis B-Annual Epidemiological Report for 2019. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/AER-Hepatitis-B-2019.pdf (accessed on 23 November 2022).
  8. Istituto Superiore di Sanità (ISS). Bollettino SEIEVA Epidemiologia Delle Epatiti Virali Acute in Italia, Numero 10-aggiornamento 2021. March 2022. Available online: https://www.epicentro.iss.it/epatite/bollettino/Bollettino-n-10-marzo-2022.pdf (accessed on 27 July 2022).
  9. Istituto Superiore di Sanità (ISS). Epidemiologia-dati SEIEVA. Available online: https://www.epicentro.iss.it/epatite/dati-seieva (accessed on 27 July 2022).
  10. Law 27 May 1991, n. 165. Obbligatorietà Della Vaccinazione Contro L’epatite Virale B. Gazz. Uff. 1° giugno 1991, n. 127. Available online: https://www.gazzettaufficiale.it/eli/id/1991/06/01/091G0201/sg (accessed on 27 July 2022).
  11. Da Villa, G.; Sepe, A. Immunization programme against hepatitis B virus infection in Italy: Cost-effectiveness. Vaccine 1999, 17, 1734–1738. [Google Scholar] [CrossRef]
  12. Boccalini, S.; Taddei, C.; Ceccherini, V.; Bechini, A.; Levi, M.; Bartolozzi, D.; Bonanni, P. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: An a posteriori evaluation and forecast of future benefits. Hum. Vaccin Immunother. 2013, 9, 1119–1128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Istituto Nazionale di Statistica (ISTAT); GeoDemo. Popolazione Residente. Available online: https://demo.istat.it/index.php (accessed on 27 July 2022).
  14. Istituto Nazionale di Statistica (ISTAT). GeoDemo. Speranza di Vita Alla Nascita. Available online: https://demo.istat.it/tvm2016/index.php?lingua=ita (accessed on 27 July 2022).
  15. Stroffolini, T.; Pasquini, P.; Mele, A. HBsAg carriers among pregnant women in Italy: Results from the screening during a vaccination campaign against hepatitis B. Public Health 1988, 102, 329–333. [Google Scholar] [CrossRef] [PubMed]
  16. Stroffolini, T.; Pasquini, P.; Mele, A. A nationwide vaccination programme in Italy against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. Vaccine 1989, 7, 152–154. [Google Scholar] [CrossRef]
  17. Stroffolini, T.; Pasquini, P. Five years of vaccination campaign against hepatitis B in Italy in infants of hepatitis B surface antigen carrier mothers. Ital. J. Gastroenterol. 1990, 22, 195–197. [Google Scholar] [PubMed]
  18. Ministry of Health. Vaccinazioni dell’età Pediatrica. Available online: https://www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id=20 (accessed on 27 July 2022).
  19. Istituto Nazionale di Statistica (ISTAT). Indice dei Prezzi al Consumo per le Rivalutazioni Monetarie. Available online: https://www.istat.it/it/archivio/30440 (accessed on 15 September 2022).
  20. Fattovich, G. Natural history of hepatitis B. J. Hepatol. 2003, 39 (Suppl. S1), S50–S58. [Google Scholar] [CrossRef]
  21. Gentilini, P.; Laffi, G.; La Villa, G.; Romanelli, R.G.; Buzzelli, G.; Casini-Raggi, V.; Melani, L.; Mazzanti, R.; Riccardi, D.; Pinzani, M.; et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am. J. Gastroenterol. 1997, 92, 66–72. [Google Scholar]
  22. Lok, A.S.; McMahon, B.J. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001, 34, 1225–1241. [Google Scholar] [CrossRef] [Green Version]
  23. McMahon, B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49 (Suppl. S5), S45–S55. [Google Scholar] [CrossRef] [PubMed]
  24. De Jongh, F.E.; Janssen, H.L.; de Man, R.A.; Hop, W.C.; Schalm, S.W.; van Blankenstein, M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103, 1630–1635. [Google Scholar] [CrossRef] [PubMed]
  25. Santi, V.; Buccione, D.; Di Micoli, A.; Fatti, G.; Frigerio, M.; Farinati, F.; Del Poggio, P.; Rapaccini, G.; Di Nolfo, M.A.; Benvegnù, L.; et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J. Hepatol. 2012, 56, 397–405. [Google Scholar] [CrossRef] [PubMed]
  26. Cucchetti, A.; Cescon, M.; Trevisani, F.; Morelli, M.C.; Ercolani, G.; Pellegrini, S.; Erroi, V.; Bigonzi, E.; Pinna, A.D. What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? Dig. Liver Dis. 2012, 44, 523–529. [Google Scholar] [CrossRef] [PubMed]
  27. Vitale, A.; Volk, M.L.; Pastorelli, D.; Lonardi, S.; Farinati, F.; Burra, P.; Angeli, P.; Cillo, U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010, 51, 165–173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Goldstein, S.T.; Zhou, F.; Hadler, S.C.; Bell, B.P.; Mast, E.E.; Margolis, H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 2005, 34, 1329–1339. [Google Scholar] [CrossRef] [Green Version]
  29. Boccalini, S.; Pellegrino, E.; Tiscione, E.; Pesavento, G.; Bechini, A.; Levi, M.; Rapi, S.; Mercurio, S.; Mannelli, F.; Peruzzi, M.; et al. Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination. Hum. Vaccin Immunother. 2013, 9, 636–641. [Google Scholar] [CrossRef] [Green Version]
  30. Bonanni, P.; Pesavento, G.; Bechini, A.; Tiscione, E.; Mannelli, F.; Benucci, C.; Nostro, A.L. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003, 21, 685–691. [Google Scholar] [CrossRef]
  31. Zanella, B.; Bechini, A.; Boccalini, S.; Sartor, G.; Tiscione, E.; Working Group Dhs; Working Group AOUMeyer; Working Group Ausltc; Bonanni, P.; Hepatitis, B. Seroprevalence in the Pediatric and Adolescent Population of Florence (Italy): An Update 27 Years after the Implementation of Universal Vaccination. Vaccines 2020, 8, 156. [Google Scholar] [CrossRef] [Green Version]
  32. Mele, A.; Tosti, M.E.; Mariano, A.; Pizzuti, R.; Ferro, A.; Borrini, B.; Zotti, C.; Lopalco, P.; Curtale, F.; Balocchini, E.; et al. National Surveillance System for Acute Viral Hepatitis (SEIEVA) Collaborating Group. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: Areas of improvement and emerging challenges. Clin. Infect. Dis. 2008, 46, 868–875. [Google Scholar] [CrossRef] [Green Version]
  33. Istituto Superiore di Sanità (ISS). Bollettino SEIEVA Epidemiologia Delle Epatiti Virali Acute in Italia, Numero 8-aggiornamento 2020; March 2021. Available online: https://www.epicentro.iss.it/epatite/bollettino/Bollettino-n-8-marzo-2021.pdf (accessed on 27 July 2022).
  34. Istituto Superiore di Sanità (ISS). Bollettino SEIEVA Epidemiologia Delle Epatiti Virali Acute in Italia, Numero 6-aggiornamento 2019; March 2020. Available online: https://www.epicentro.iss.it/epatite/bollettino/Bollettino-n-6-marzo-2020.pdf (accessed on 27 July 2022).
  35. Istituto Superiore di Sanità (ISS). Bollettino SEIEVA Epidemiologia Delle Epatiti Virali Acute in Italia_Numero 4-aggiornamento 2018; march 2019. Available online: https://www.epicentro.iss.it/epatite/bollettino/Bollettino-4-marzo-2019.pdf (accessed on 27 July 2022).
  36. Pinon, M.; Giugliano, L.; Nicastro, E.; Kakaa, O.; Coscia, A.; Carbonara, C.; D’Antiga, L.; Calvo, P.L. Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy. Vaccines 2021, 9, 801. [Google Scholar] [CrossRef] [PubMed]
  37. Conferenza Permanente Per i Rapporti Tra Lo Stato Le Regioni e Le Province Autonome di Trento e Bolzano. Intesa 19 gennaio 2017. Intesa, ai sensi dell’articolo 8, comma 6, della legge 5 giugno 2003, n. 131, tra il Governo, le regioni e le province autonome di Trento e Bolzano sul documento recante “Piano nazionale prevenzione vaccinale 2017–2019” (Rep. atti n. 10/CSR) (17A01195). (G.U. Serie Generale, n. 41 del 18 febbraio 2017). Available online: https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=58185 (accessed on 28 July 2022).
  38. Istituto Nazionale di Statistica (ISTAT). Natalità e Fecondità Della Popolazione Residente. ANN0 2020. Statistiche report dicembre 2021. Available online: https://www.istat.it/it/files//2021/12/REPORT-NATALITA-2020.pdf (accessed on 21 October 2022).
  39. Ahmad, A.A.; Falla, A.M.; Duffell, E.; Noori, T.; Bechini, A.; Reintjes, R.; Veldhuijzen, I.K. Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries. BMC Infect. Dis. 2018, 18, 34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Istituto Superiore di Sanità (ISS). Epatite, B. Available online: https://www.epicentro.iss.it/epatite/epatite-b (accessed on 21 October 2022).
  41. Mariano, A.; Mele, A.; Tosti, M.E.; Parlato, A.; Gallo, G.; Ragni, P.; Zotti, C.; Lopalco, P.; Pompa, M.G.; Graziani, G.; et al. Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy. J. Med. Virol. 2004, 74, 216–220. [Google Scholar] [CrossRef] [PubMed]
  42. Bechini, A.; Bonanni, P.; Grazzini, M.; Paolini, D.; Arcangeli, G.; Mucci, N.; Bini, C.; Tiscione, E.; Zanella, B.; Boccalini, S. Need to take special care of non-responders to hepatitis B vaccination among health-care workers, students and chronic patients. Hum. Vaccin Immunother. 2021, 17, 580–582. [Google Scholar] [CrossRef] [PubMed]
  43. Sixty-Third World Health Assembly–WHA63.18. Agenda Item 11.12. Viral Hepatitis. 21 May 2010. Available online: https://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R18-en.pdf (accessed on 30 December 2021).
  44. Sixty-Seventh World Health Assembly-WHA67.6. Agenda item 12.3. Hepatitis. 24 May 2014. Available online: https://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf (accessed on 30 December 2021).
  45. World Health Organization (WHO). Global Health Sector Strategy on Viral Hepatitis 2016–2021 towards Ending Viral Hepatitis. Available online: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1&isAllowed=y (accessed on 30 December 2021).
  46. Ministry of Health. Piano Nazionale Per La Prevenzione Delle Epatiti Virali da Virus B e C (PNEV). 27 October 2015. Available online: https://www.salute.gov.it/imgs/C_17_pubblicazioni_2437_allegato.pdf (accessed on 30 December 2021).
  47. World Health Organization (WHO). Interim Guidance for Country Validation of Viral Hepatitis Elimination. World Health Organization: Geneva, Switzerland. Available online: https://www.who.int/publications/i/item/9789240028395 (accessed on 28 July 2022).
  48. Signorelli, C. Quarant’anni (1978–2018) di Politiche Vaccinali in Italia [Forty Years (1978–2018) of Vaccination Policies in Italy]. Acta Biomed. 2019, 90, 127–133. [Google Scholar] [CrossRef]
  49. Presidente della Repubblica Italiana. Law 31 July 2017, n. 119. Conversione in Legge, con Modificazioni, del Decreto-Legge 7 Giugno 2017, n. 73, Recante Disposizioni Urgenti in Materia di Prevenzione Vaccinale. In Gazzetta Ufficiale Serie Generale, n. 182 del 5 August 2017. Available online: https://www.gazzettaufficiale.it/eli/id/2017/08/5/17G00132/sg (accessed on 28 July 2022).
Ijerph 19 16365 g001 550
Figure 1. Natural history of HBV infection applied to the mathematical model.
Figure 1. Natural history of HBV infection applied to the mathematical model.
Ijerph 19 16365 g001
Ijerph 19 16365 g002 550
Figure 2. Reduction rate of clinical costs due to implementation of the vaccination program from the NHS perspective (AHB: Acute Hepatitis B; CHB: Chronic Hepatitis B; CC: Compensated Cirrhosis; DC: Decompensated Cirrhosis; HCC: Hepatocellular carcinoma; LT: Liver Transplantation).
Figure 2. Reduction rate of clinical costs due to implementation of the vaccination program from the NHS perspective (AHB: Acute Hepatitis B; CHB: Chronic Hepatitis B; CC: Compensated Cirrhosis; DC: Decompensated Cirrhosis; HCC: Hepatocellular carcinoma; LT: Liver Transplantation).
Ijerph 19 16365 g002
Table
Table 1. Assumed data used for the model (AHB: Acute Hepatitis B; CHB: Chronic Hepatitis B; CC: Compensated Cirrhosis; DC: Decompensated Cirrhosis; HCC: Hepatocellular Carcinoma; LT: Liver Transplantation).
Table 1. Assumed data used for the model (AHB: Acute Hepatitis B; CHB: Chronic Hepatitis B; CC: Compensated Cirrhosis; DC: Decompensated Cirrhosis; HCC: Hepatocellular Carcinoma; LT: Liver Transplantation).
Stage of the DiseaseTime Interval Between StagesMedian Age of PatientsSurvival RateReference
CHB-31Equal to life expectancy for the general population[14,20]
CC15 years from CHB4699.1% at 5 years[20,21,22,23,24]
76.8% at 10 years
49.4% at 15 years
25% at 20 years
0% at 25 years
DC3 years from CC4914% at 5 years[20]
HCC44 months from CC5078.7% at 1 years[20,25]
50.4% at 3 years
28.9% at 5 years
LT3 months from HCC or DC-5% of patients with LT encounter transplant-related death[26,27]
72% post-transplant survival rate at 5 years
Table
Table 2. Annual clinical costs of HBV diseases (referring to 1990) and hepatitis-B-vaccination costs (referring to 1991) for Acute Hepatitis B (AHB), Chronic Hepatitis B (CHB), Compensated Cirrhosis (CC) and Hepatocellular Carcinoma (HCC).
Table 2. Annual clinical costs of HBV diseases (referring to 1990) and hepatitis-B-vaccination costs (referring to 1991) for Acute Hepatitis B (AHB), Chronic Hepatitis B (CHB), Compensated Cirrhosis (CC) and Hepatocellular Carcinoma (HCC).
Annual Cost of HBV Diseases (1990)
Annual assistance costs/case
  AHB9296 EUR
  CHB and Cirrhosis (hospital and home assistance)7230 EUR
  HCC27,889 EUR
Annual social costs/case
  AHB1916 EUR
  CHB and Cirrhosis1277 EUR
  HCC11,654 EUR
HBV Vaccination Costs (1991)
Direct costs
  Vaccine6.20 EUR/dose (pediatric dose)
9.30 EUR/dose (adult dose)
  Vaccine preservation0.09 EUR/dose
  Vaccine administration6.45 EUR/person
  Treatment of side effects (1% of vaccine doses administered)4.93 EUR/case
  Immuno-prophylaxis treatment of babies born to HBsAg-positive mothers14.98 EUR/newborn
Indirect costs
  Lost working-days for vaccination7.98 EUR/dose
  Missed working-days for treatment of side effects (1% of vaccine-doses administered)21.17 EUR/dose
Table
Table 3. Total number of clinical cases related to HBV infection in Italy (AHB: Acute Hepatitis B; CHB: Chronic Hepatitis B; CC: Compensated Cirrhosis; DC: Decompensated Cirrhosis HCC: Hepatocellular carcinoma; LT: Liver Transplantation).
Table 3. Total number of clinical cases related to HBV infection in Italy (AHB: Acute Hepatitis B; CHB: Chronic Hepatitis B; CC: Compensated Cirrhosis; DC: Decompensated Cirrhosis HCC: Hepatocellular carcinoma; LT: Liver Transplantation).
1991–2020No VaccinationVaccinationPrevented CasesReduction Rate (%)
HBV infection237,07443,701193,37382
AHB61,32930,93130,39750
CHB76701414625682
CC143628157
DC104657
HCC120239781
LT3272579
Table
Table 4. Direct, indirect and total clinical-costs (in euros) during the period 1991–2020, 2021–2070 and 1991–2070 in the no-vaccination and vaccination scenario.
Table 4. Direct, indirect and total clinical-costs (in euros) during the period 1991–2020, 2021–2070 and 1991–2070 in the no-vaccination and vaccination scenario.
1991–2020Direct Costs (EUR)Indirect Costs (EUR)Total Costs (EUR)Reduction of Direct Costs (%)Reduction of Indirect Costs (%)Total Reduction Rate (%)
No VaccinationVaccinationDifferenceNo VaccinationVaccinationDifferenceNo VaccinationVaccinationDifference
AHB890,904,717404,044,092486,860,625183,575,86683,255,530100,320,3371,074,480,584487,299,622587,180,962555555
CHB1,516,037,546384,847,9601,131,189,587267,688,91567,953,154199,735,7611,783,726,462452,801,1131,330,925,348757575
CC34,501,50715,965,69918,535,8086,091,9802,819,0863,272,89440,593,48718,784,78521,808,702545454
DC2,000,214915,5891,084,625353,181161,667191,5142,353,3951,077,2561,276,138545454
HCC23,665,1807,311,01316,354,1664,650,2361,473,0593,177,17728,315,4168,784,07219,531,343696869
LT8,145,3592,427,4135,717,9451,294,608364,472930,1379,439,9672,791,8856,648,082707270
Total2,475,254,523815,511,7671,659,742,756463,654,787156,026,968307,627,8192,938,909,310971,538,7351,967,370,576676667
2021–2070No VaccinationVaccinationDifferenceNo VaccinationVaccinationDifferenceNo VaccinationVaccinationDifferenceReduction of Direct Costs (%)Reduction of Indirect Costs (%)Total Reduction Rate (%)
AHB000000000000
CHB1,984,954,476280,420,2131,704,534,263350,486,24749,514,198300,972,0502,335,440,724329,934,4112,005,506,313868686
CC13,827,3305,061,5348,765,7962,441,511893,7221,547,78916,268,8425,955,25610,313,585636363
DC444,275137,385306,88978,44624,25854,188522,721161,644361,077696969
HCC103,880,97320,231,67183,649,30318,850,1373,604,56715,245,570122,731,11023,836,23898,894,873818181
LT6,206,322695,1485,511,174446,90727,434419,4736,653,229722,5825,930,647899489
Total2,109,313,376306,545,9511,802,767,425372,303,24954,064,179318,239,0702,481,616,625360,610,1302,121,006,495858585
1991–2070No VaccinationVaccinationDifferenceNo VaccinationVaccinationDifferenceNo VaccinationVaccinationDifferenceReduction of Direct Costs (%)Reduction of Indirect Costs (%)Total Reduction Rate (%)
AHB890,904,717404,044,092486,860,625183,575,86683,255,530100,320,3371,074,480,584487,299,622587,180,962555555
CHB3,500,992,022665,268,1732,835,723,850618,175,163117,467,352500,707,8114,119,167,185782,735,5243,336,431,661818181
CC48,328,83721,027,23327,301,6058,533,4923,712,8094,820,68356,862,32924,740,04132,122,288565656
DC2,444,4881,052,9751,391,514431,627185,925245,7022,876,1151,238,9001,637,215575757
HCC127,546,15327,542,684100,003,46923,500,3735,077,62618,422,747151,046,52632,620,310118,426,216787878
LT14,351,6813,122,56111,229,1201,741,515391,9061,349,61016,093,1963,514,46712,578,729787778
Total 4,584,567,8991,122.057,7183,462,510,182835,958,036210,091,147625,866,8895,420,525,9351,332,148,8654,088,377,071767575
Table
Table 5. Costs/Savings (in EUR) and ROI/BCR during the first 30 years of the vaccination program (1991–2020) and in the overall period (1991–2070).
Table 5. Costs/Savings (in EUR) and ROI/BCR during the first 30 years of the vaccination program (1991–2020) and in the overall period (1991–2070).
Period 1991–2020
NHS PerspectiveSocietal Perspective
Clinical savings (EUR)1,967,370,5761,967,370,576
Vaccination costs (EUR)1,263,247,8301,484,792,906
Net costs (EUR)−396,494,926−482,577,670
ROI/BCR1.311.33
Overall Period 1991–2070
NHS PerspectiveSocietal Perspective
Clinical savings (EUR)3,462,510,1824,088,377,071
Vaccination costs (EUR)1,263,247,8301,484,792,906
Net costs (EUR)−2,199,262,351−2,603,584,165
ROI/BCR2.742.75
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Boccalini, S.; Bonito, B.; Zanella, B.; Liedl, D.; Bonanni, P.; Bechini, A. The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile. Int. J. Environ. Res. Public Health 2022, 19, 16365. https://doi.org/10.3390/ijerph192316365

AMA Style

Boccalini S, Bonito B, Zanella B, Liedl D, Bonanni P, Bechini A. The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile. International Journal of Environmental Research and Public Health. 2022; 19(23):16365. https://doi.org/10.3390/ijerph192316365

Chicago/Turabian Style

Boccalini, Sara, Benedetta Bonito, Beatrice Zanella, Davide Liedl, Paolo Bonanni, and Angela Bechini. 2022. "The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile" International Journal of Environmental Research and Public Health 19, no. 23: 16365. https://doi.org/10.3390/ijerph192316365

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop